«上一篇/Previous Article|本期目录/Table of Contents|下一篇/Next Article»

《中华肺部疾病杂志》[ISSN:1006-6977/CN:61-1281/TN]

卷:

期数:

2025年03期

页码:

345-349

栏目:

论著

出版日期:

2025-06-25

文章信息/Info

Title:

Study on serum miR-21 and miR-937-3p expression changes in early stage non-small cell lung cancer patients before and after surgery

作者:

赵雅波¹; 王 倩²; 闫小龙¹; 王元勇³; 何改花⁴; 郭一泽¹

710038 西安,空军军医大学第二附属医院胸腔外科¹
266011 青岛,康复大学青岛医院(青岛市立医院)妇科²
100142 北京,北京大学肿瘤医院胸外一科³
710038 西安,空军军医大学第二附属医院内分泌科⁴

Author(s):

Zhao Yabo¹;  Wang Qian²;  Yan Xiaolong¹;  Wang Yuanyong³;  He Gaihua⁴;  Guo Yize¹.

¹Department of Thoracic Surgery, The Second Affiliated Hospital of Air Force Military Medical University, Xi'an 710038, China; ²Department of Gynecology, Qingdao Hospital, University of Health and Rehabilitation Sciences(Qingdao Municipal Hospital), Qingdao 266011, China; ³Department of Thoracic Surgery, Peking University Cancer Hospital, Beijing 100142, China; ⁴Department of Endocrinology, The Second Affiliated Hospital of Air Force Medical University, Xi'an 710038, China

关键词:

非小细胞肺癌;  生物标记物;  微小RNA;  诊断

Keywords:

Biomarkers;  Non-small cell lung cancer;  MicroRNA;  Prognosis;  Diagnosis

分类号:

R734.2

DOI:

10.3877/cma.j.issn.1674-6902.2025.03.001

摘要:

目的 微RNA(miRNA)在基因表达的转录后调控中起着关键作用,已成为恶性肿瘤发生、发展和转移的重要调控因子。收集非小细胞肺癌(non-small cell lung caner, NSCLC)患者术前和术后3个月的血清样本中mir-21、mir-671-5p、mir-937-3p和mir-611的表达谱,分析生物标志物的潜力。方法 采集 62例早期NSCLC患者术前和术后3个月的血液样本。采用定量实时聚合酶链式反应(polymerase chain reaction, PCR)技术对血清中mir-21、mir-671-5p、mir-937-3p和mir-611 的相对表达水平进行量化。结果 术前和术后3个月比较,患者术后血清miR-21下降 0.2584倍(95%CI: 0.05664～0.4601)、miR-671-5p下降0.2213倍(95%CI: 0.02188～0.4207)、miR-937-3p下降0.2182倍(95%CI: 0.05234～0.3840)和miR-611下降0.6224倍(95%CI:0.4426～0.8021),分子表达水平低于手术前(P=0.0039,P=0.0154,0.0031,P<0.0001)。特征曲线(receiver operating characteristic curve, ROC)分析表明,miR-21(AUC=0.6942,P=0.0004)和 miR-937-3p(AUC=0.6522,P=0.0059)能以相对较高的准确度区分 NSCLC病例术前术后水平,基因的血清水平与患者的临床特征之间没有发现明显的相关性。miR-671-5p 术前的 NSCLC 样本中显示出上调,但AUC 值为 0.5974(P= 0.0783),显示其不适合作为 NSCLC的生物标志物。miR-611的AUC为0.5630(P=0.2548),不适合作为 NSCLC生物标志物。依数据结果,miR-21和 miR-937-3p有可能成为筛选 NSCLC的生物标志物。结论 血清中miR-21和miR-937-3p有望在早期NSCLC患者中成为诊断和预后的潜在生物标志物。

Abstract:

Objective MicroRNAs(miRNAs)play a key role in the post-transcriptional regulation of gene expression and have emerged as important regulators of cancer onset, progression and metastasis. The aim of this study was to evaluate the expression profiles of mir-21, mir-671-5p, mir-937-3p, and mir-611 in preoperative and three-month postoperative serum samples from patients with early-non-small cell lung caner(NSCLC)in order to explore their biomarker potential. Methods A total of 62 blood samples from early-NSCLC patients(pre- and post-surgery)were collected. The relative expression levels of mir-21, mir-671-5p, mir-937-3p and mir-611 in serum were quantified using quantitative real-time PCR. Results Our results showed that comparing preoperative and postoperative 3 months, patients'postoperative serum miR-21 decreased 0.2584-fold(95%CI: 0.05664～0.4601), miR-671-5p decreased 0.2213-fold(95%CI: 0.02188～0.4207), miR-937-3p decreased 0.2182-fold(95%CI: 0.05234～0.3840)and miR-611 decreased 0.6224-fold(95%CI: 0.4426～0.8021), and the expression levels of the above molecules were significantly lower than those before surgery(P=0.0039, 0.0154, 0.0031, <0.0001). Receiver operating characteristic curve(ROC)analysis showed that miR-21(AUC=0.6942, P=0.0004)and miR-937-3p(AUC=0.6522, P=0.0059)were able to differentiate with relatively high accuracy between the preoperative and postoperative levels in early-NSCLC patients. However, no significant correlation was found between the serum levels of the studied genes and the clinical characteristics of the patients. Conclusion Serum miR-21 and miR-937-3p are expected to be potential biomarkers for diagnosis and prognosis in early-NSCLC patients.

参考文献/References:

1 Siegel RL, Giaquinto AN, Jemal A. Cancer statistics, 2024[J]. CA Cancer J Clin, 2024, 74(1): 12-49.
2 Zhou Q, Yu Y, Xing L, et al. First-line zorifertinib for EGFR-mutant non-small cell lung cancer with central nervous system metastases: The phase 3 EVEREST trial[J]. Med, 2024, 6(1): 100513.
3 Wang Y, Xu R, Zhang D, et al. Circ-ZKSCAN1 regulates FAM83A expression and inactivates MAPK signaling by targeting miR-330-5p to promote non-small cell lung cancer progression[J]. Transl Lung Cancer Res, 2019, 8(6): 862-875.
4 骆晨雨, 周月阳, 李 娜, 等. 中国癌症疾病负担及三级预防现状[J]. 中华流行病学杂志, 2024, 45(5): 621-625.
5 Zhu J, Yang J, Chen X, et al. Integrated bulk and single-cell RNA sequencing data constructs and validates a prognostic model for non-small cell lung cancer [J]. J Cancer, 2024, 15(3): 796-808.
6 Xu JY, Zhang C, Wang X, et al. Integrative proteomic characterization of human lung adenocarcinoma[J]. Cell, 2020, 182(1): 245-261 e17.
7 曹立宇, 田壮壮, 祝利利, 等. WHO(2020)女性生殖系统肿瘤分子分型在子宫内膜癌中的应用与临床意义[J]. 临床与实验病理学杂志, 2024, 40(3): 279-284.
8 Mcgranahan N, Swanton C. Clonal heterogeneity and tumor evolution:Past, present, and the Future[J]. Cell, 2017, 168(4): 613-628.
9 Lin S, Gregory RI. MicroRNA biogenesis pathways in cancer[J]. Nat Rev Cancer, 2015, 15(6): 321-333.
10 Wang L, Hu Z, Bai H, et al. miRNA-105-5p regulates the histone deacetylase HDAC2 through FOXG1 to affect the malignant biological behavior of triple-negative breast cancer cells[J]. Am J Med Sci, 2024:S0002-9629(24)01476-9.
11 Tai MC, Bantis LE, Parhy G, et al. Circulating microRNA panel for prediction of recurrence and survival in early-stage Lung Adenocarcinoma[J]. Int J Mol Sci, 2024, 25(4): 2331.
12 D'agostino E, Muro A, Sgueglia G, et al. Exosomal microRNAs: Comprehensive methods from exosome isolation to miRNA extraction and purity analysis[J]. Methods Mol Biol, 2023, 2595: 75-92.
13 Cheng Z, Kong Y, Xu H, et al. Extracellular vesicles derived from stored red blood cell suspensions enhance invasion and migration of lung cancer cells by miR1246 and miR150-3p[J]. Vox Sang, 2024, 119(8): 809-820.
14 Siniscalco D, Galderisi U, Peluso G, et al. Circulating microRNAs in cancer: A 5-year update with a focus on breast and lung cancers[J]. Int J Mol Sci, 2024, 25(6): 3140.
15 Dai H, Li L, Yang Y, et al. Screening microRNAs as potential prognostic biomarkers for lung adenocarcinoma[J]. Ann Med, 2023, 55(2): 2241013.
16 Ezzatifar F, Rafiei A, Valadan R, et al. Detection of novel autoantibodies to nucleolin's RNA-binding domains as a serum tumor biomarker through ELISA[J]. Iran J Allergy Asthma Immunol, 2022, 21(6): 616-625.
17 Xi Y, Zhang Y, Fang J, et al. Development of monoclonal antibodies and characterization of an ELISA platform against kallikrein-related peptidase 6 as a tumor biomarker[J]. Monoclon Antib Immunodiagn Immunother, 2015, 34(5): 346-353.
18 Rizou T, Perlikos F, Lagiou M, et al. Development of novel real-time RT-qPCR methodologies for quantification of the COL11A1 mRNA general and C transcripts and evaluation in non-small cell lung cancer specimens[J]. J BUON, 2018, 23(6): 1699-1710.
19 Li Y, Zhou B, Yang Y, et al. Expression and clinical relevance of serum LncRNA NEAT1 and microRNA-31 in patients with advanced lung cancer and pulmonary infection[J]. Altern Ther Health Med, 2024: AT9614.
20 Kang JE, Kim H, Lee YH, et al. Unveiling Cas12j trans-cleavage activity for CRISPR diagnostics: Application to miRNA detection in lung cancer diagnosis[J]. Adv Sci(Weinh), 2024, e2402580.
21 杨 慧, 郭丽娟, 冯晓丹, 等. 非小细胞肺癌铂类药物耐药mi RNA表达特征及预测分析[J/CD]. 中华肺部疾病杂志(电子版), 2024, 17(5): 719-724.
22 Yadav R, Khatkar R, Yap KC, et al. The miRNA and PD-1/PD-L1 signaling axis: an arsenal of immunotherapeutic targets against lung cancer[J]. Cell Death Discov, 2024, 10(1): 414.
23 Tanigawa K, Misono S, Mizuno K, et al. MicroRNA signature of small-cell lung cancer after treatment failure: impact on oncogenic targets by miR-30a-3p control[J]. Mol Oncol, 2023, 17(2): 328-343.
24 Aguilar-Martinez SY, Campos-viguri GE, Medina-Garcia SE, et al. MiR-21 regulates growth and migration of cervical cancer cells by RECK signaling pathway[J]. Int J Mol Sci, 2024, 25(7): 4086.
25 戴 随, 张贺平, 褚翔南, 等. miR-325-3p通过CCL19基因调控非小细胞肺癌脑部转移的发展[J]. 河南大学学报(医学版), 2024, 43(1): 35-41.
26 Desouky EM, Khaliefa AK, Hozayen WG, et al. Signature of miR-21 and MEG-2 and their correlation with TGF-beta signaling in breast cancer[J]. Hum Exp Toxicol, 2023, 42: 9603271231159799.
27 Bostanshirin N, Hajikhani B, Vaezi AA, et al. Association between colorectal cancer and expression levels of miR-21, miR-17-5P, miR-155 genes and the presence of Fusobacterium nucleatum in biopsy samples obtained from Iranian patients[J]. Infect Agent Cancer, 2023, 18(1): 14.
28 Asghariazar V, Makaremi S, Zare E, et al. Oleuropein induces apoptosis in gastric cancer cell lines by regulating mir-34a, mir-21, and related genes: an experimental and bioinformatic study[J]. Int J Biol Macromol, 2024, 265(Pt 1): 130527.
29 Ma Z, Chen G, Chen Y, et al. MiR-937-3p promotes metastasis and angiogenesis and is activated by MYC in lung adenocarcinoma[J]. Cancer Cell Int, 2022, 22(1): 31.

备注/Memo

备注/Memo:

基金项目: 国家自然基金资助项目(8217111370)
西安市创新能力支撑计划(23YXYJ0171)
通信作者: 郭一泽, Email: 289307575@qq.com

常用功能

更新日期/Last Update: 2025-06-25